*November 2023*
Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.
The EGFR Resisters is a global community of patients and caregivers impacted by EGFR-positive lung cancer. We’re here to share knowledge, offer support and collaborate to drive progress in research and care. We are here to share treatment experiences, information about clinical trials, breaking news about research developments, and other information with each other.